α1-Acid Glycoprotein Attenuates Adriamycin-Induced Nephropathy via CD163 Expressing Macrophage Induction : Kidney360

Journal Logo

Original Investigations: Acute Kidney Injury and ICU Nephrology

α1-Acid Glycoprotein Attenuates Adriamycin-Induced Nephropathy via CD163 Expressing Macrophage Induction

Fujimura, Rui; Watanabe, Hiroshi; Nishida, Kento; Fujiwara, Yukio; Koga, Tomoaki; Bi, Jing; Imafuku, Tadashi; Kobayashi, Kazuki; Komori, Hisakazu; Miyahisa, Masako; Maeda, Hitoshi; Tanaka, Motoko; Matsushita, Kazutaka; Wada, Takashi; Fukagawa, Masafumi; Maruyama, Toru

Author Information
Kidney360 1(5):p 343-353, May 2020. | DOI: 10.34067/KID.0000782019
  • Free
  • Infographic
  • SDC



Recent clinical studies have shown that proteinuria is a critical factor in the progression of CKD and onset of cardiovascular disease. Inflammation and infiltration of macrophages into renal tissue are implicated as causes of proteinuria. α1-Acid glycoprotein (AGP), an acute-phase plasma protein, is leaked into the urine in patients with proteinuria. However, the relationship between urinary leakage of AGP, renal inflammation, and proteinuria remains unclear.


Human AGP (hAGP) was exogenously administrated for 5 consecutive days to adriamycin-induced nephropathy model mice.


Adriamycin treatment increased urinary AGP, accompanied by decreased plasma AGP in mice. Exogenous hAGP administration to adriamycin-treated mice suppressed proteinuria, renal histologic injury, and inflammation. hAGP administration increased renal CD163 expression, a marker of anti-inflammatory macrophages. Similar changes were observed in PMA-differentiated THP-1 cells treated with hAGP. Even in the presence of LPS, hAGP treatment increased CD163/IL-10 expression in differentiated THP-1 cells.


AGP alleviates proteinuria and renal injury in mice with proteinuric kidney disease via induction of CD163-expressing macrophages with anti-inflammatory function. The results demonstrate that endogenous AGP could work to protect against glomerular disease. Thus, AGP supplementation could be a possible new therapeutic intervention for patients with glomerular disease.

Visual Abstract



Approximately 13% of the worldwide population suffer from CKD, and the number of patients is increasing year by year (1). CKD not only leads to ESKD, but is also associated with a high risk of death from cardiovascular disease (CVD) (2). In previous clinical trials, proteinuria was reported as a critical factor involved in the progression of CKD and onset of CVD (234). In fact, nephrotic patients with massive proteinuria have a 5.5-fold higher risk of CVD than matched controls (5). It has been reported that inflammation and infiltration of immune cells into renal tissue are a cause of proteinuria. In addition, the onset of proteinuria further induces inflammation in tubular cells (6,7). Therefore, it is important to stop the vicious cycle induced by persistent proteinuria and inflammation, for the prevention of CKD progression and onset of CVD.

Recently, the involvement of macrophages in inflammation in renal pathologies has been reported (8,9). Macrophages have phenotypes that are classify them as M1 macrophages (classically activated macrophages) or M2 macrophages (alternatively activated macrophages). In general, M1 macrophages promote inflammation and play a central role in host defense during infection. In contrast, M2 macrophages are involved in anti-inflammation and tissue remodeling (10). These phenotypes can be changed in response to a disease state. M1 macrophages predominate in the early injury phase, whereas M2 macrophages predominate in the recovery and repair phase (11). Indeed, previous reports have demonstrated that administration of M2 macrophages induced by IL-4 or IL-4/IL-13 is effective against renal injury resulting from ischemia reperfusion or adriamycin (ADR)-induced nephropathy in mice (11,12). These studies suggest that regulation of macrophage phenotypes in the kidney could be important in reducing renal inflammation and proteinuria.

α1-Acid glycoprotein (AGP), also known as orosomucoid, is a heavily glycosylated serum protein with five branched N-glycans containing negatively charged sialic acids (13,14). Therefore, AGP has the lowest pI value of all plasma proteins (pI=2.7–3.2). In addition, AGP is classified as one of the major acute-phase proteins in mammals and is known that its serum concentration increases two- to five-fold during inflammation (15). In patients with proteinuria, it has been observed that AGP leaks into urine (16,17). On the other hand, AGP has been reported to possesses unique biologic activities. For example, in vitro experiments have demonstrated that AGP modulates the activation of neutrophils, lymphocytes, and monocytes (14,18–192021). Daemen et al. (22) reported that exogenously administered AGP attenuates renal ischemia reperfusion injury in vivo, although its renoprotective mechanisms remain unclear. Importantly, we have previously found that AGP weakly activates the Toll-like receptor 4 (TLR4)/CD14 pathway and increases the expression of CD163, a cysteine-rich scavenger receptor in macrophages, particularly of the M2 phenotype (23,24). Interestingly, CD163-overexpressing macrophages inhibit LPS-induced inflammation in vitro (25). Furuhashi et al. (26) also found that CD163-expressing macrophages are associated with IL-10 production as an anti-inflammatory cytokine in anti-glomerular basement membrane GN rats. These findings have led to the idea that AGP may potentiate the suppression of renal inflammation and proteinuria by changing the macrophage phenotype to one with enhanced CD163 expression.

The purpose of this study is to clarify whether exogenously administered human AGP (hAGP) attenuates renal damage in ADR-induced nephropathy mice. In addition, possible mechanisms of this renoprotective effect are examined. Here, we provide evidence that administration of hAGP induces CD163-expressing macrophages in the kidney, which leads to reduced proteinuria and renal inflammation in ADR-induced nephropathy mice.

Materials and Methods

Purification of AGP

hAGP was purified from supernatant of human plasma fraction V donated by KM Biologics (Kumamoto, Japan). Supernatant was diluted with acetate buffer (10 mM) and injected onto an ion exchange column (Hitrap CM,Q column; GE Healthcare, Little Chalfont, UK) at a flow rate of 3 ml/min on an AKTAprime Plus System (GE Healthcare). The bound materials were eluted with acetate buffer (10 mM) containing NaCl (0.5 mol/L). hAGP was eluted in the first peak. The eluted sample was dialyzed against distilled water at 4°C, freeze-dried, and stored at −20°C (27). The purity of hAGP was confirmed by SDS-PAGE. The secondary structure of hAGP was confirmed by circular dichroism.

Animal Studies

All animal experiments were performed according to the guidelines, principles, and procedures for the care and use of laboratory animals of Kumamoto University. All animals were housed in an environment with controlled temperature, a 12-hour light/dark cycle, and free access to food and water.

Six-week-old male BALB/c mice were obtained from Japan SLC, Inc. (Shizuoka, Japan). After randomizing mice by body weight, mice were slowly injected intravenously with saline or ADR (15 mg/kg body weight). The first administration of saline or AGP (5 mg/mouse) was intraperitoneally administered between 30 minutes and 1 hour after ADR injection, allowing for time for the ADR to disappear from the blood. Subsequently, saline or hAGP was administered at the same time for 4 consecutive days. No mice died under these experimental conditions. On day 7 and day 21 after ADR administration, urine was collected by metabolic cage for a total of 16 hours from 4:00 PM to 8:00 AM, and the urine volume measured. Mice were sacrificed at day 7 or day 21 after ADR administration. Kidneys and livers were harvested after perfusion with 0.9% NaCl. A part of the left kidney was used for quantitative RT-PCR and histologic analysis.

Renal Function

Urinary albumin was measured by ELISA (Shibayagi, Japan). BUN, creatinine, and total cholesterol were measured using FUJI DRI-CHEM (Fujifilm, Japan).

Histologic Analysis

Sections of renal tissue were stained with periodic acid-Schiff. Quantitative evaluation of glomerulosclerosis and damaged tubules was performed according to the report of Cao et al. (28). Imaging and analyses were performed using a Keyence BZ-X710 microscope (Keyence, Osaka, Japan). The images were randomly acquired, with 12–17 high-power fields collected for each mouse and then 21 glomeruli randomly traced within them. The percentage of glomerulosclerosis was computed from the area that was periodic acid-Schiff-positive in the total area of the same glomerulus. For analysis of damaged tubules, 10 high-power field images were randomly acquired of the renal cortex of each mouse. Three people counted damaged tubules, which revealed intraluminal casts, vacuolization, and droplets, and the percentage of damaged tubules was calculated using the number of damaged tubules divided by the total number of tubules. This analysis was performed in a blind manner.

Immunostaining Assay

Infiltration of macrophages was confirmed by immunostaining used anti-EMR1 antibody (F4/80; Dako, Santa Clara, CA). For each mouse, 10–12 high-power fields were randomly imaged and the number of F4/80+ cells was counted. The expression of nephrin and the renal localization of AGP were confirmed by immunofluorescence using nephrin and ORM1 antibodies. Deparaffinized sections were inactivated with Histo VT One (Nacalai Tesque, Kyoto, Japan) and incubated with nephrin (1:100; R&D Systems, Inc., Minneapolis, MN) or ORM1 antibody (1:50; Proteintech, Rosemont, IL) overnight at 4°C, followed by incubation with Alexa 488 donkey anti-goat IgG(H+L) (1:500; Abcam plc, Cambridge, UK) or Alexa 546 goat anti-rabbit IgG(H+L) (1:200; Thermo Fisher Scientific, Waltham, MA) for 90 minutes at room temperature. Images were obtained on a Keyence BZ-X710 microscope (Keyence).

Kidney Cell Suspension

Kidney cell suspension for isolating renal macrophages was prepared according to the report of Cao et al. (29). Kidneys were harvested after perfusion with HBSS (without calcium) and DMEM containing 1 mg/ml collagenase IV and 100 μg/ml DNase I (Worthington Biochemical Corp, Lakewood, NJ). Kidney tissues were cut into a paste and shaken for 40 minutes at 37°C in DMEM containing collagenase IV and DNase I. Cell suspensions were passed through a 75-μm stainless mesh and centrifuged at 180 × g for 3 minutes. The pellets were suspended in red blood cell lysis buffer and centrifuged at 300 × g for 5 minutes. After washing with PBS(−), cell suspensions were incubated for 15 minutes at 4°C in blocking buffer (2% FBS and 2 mM EDTA) containing 10 μg/ml fragment crystallizable blocker. Cell suspensions were stained with anti-CD45.2, F4/80, and antibodies to T cell, B cell, and natural killer cell lineages (TCRβ, TCRγδ, CD3ε, CD19, and CD49b).

Isolation of Renal Macrophages

Kidney cell suspensions were gated on forward scatter and SSC to remove doublets, and exclude dead cells using propidium iodide. Then, cells were gated on leukocytes using an anti-CD45.2 antibody and T cell, B cell, and natural killer cell lineages excluded. Macrophages were isolated using anti-F4/80 antibody. After sorting, RNA isolation was performed using an NucleoSpin RNA XS column (Takara Bio, Otsu, Japan).

Cell Culture

Human THP-1 cells were grown in RPMI 1640 (Gibco, Grand Island, NY) containing 10% FBS, and 1% penicillin and streptomycin (Thermo Fisher Scientific). THP-1 cells were maintained at 37°C in a 5% CO2 atmosphere. THP-1 cells were seeded at 8 × 105 cells/well in six-well plates, and differentiated by addition of 50 nM PMA for 48 hours. Cells were then washed in PBS and incubated for 24 hours. hAGP (0.5–2.5 mg/ml), which was quantified by bicinchoninic acid protein assay, was added and cells incubated for a further 48 hours. In the experiments with stimulation by LPS, hAGP (1.0 mg/ml), or IL-4 (10 ng/ml) and IL-13 (10 ng/ml), was added to the cells for 24 hours, and then cells stimulated with LPS (100 ng/ml) for 2 hours.

Western Blotting

AGP in plasma and urine was confirmed by western blotting for each mouse. Both plasma and urine samples (0.5 μl/lane) were boiled for 3 minutes at 100°C and separated by 10% SDS-PAGE. Proteins were transferred onto polyvinylidene difluoride membranes (Immobilon-P; Millipore, Billerica, MA) by wet electroblotting. The membranes were incubated in ORM1 antibody (1:5000; Proteintech). Antibody signals were detected with LAS-4000 minutes (GE Healthcare).

Quantitative RT-PCR

Total RNA from kidney and liver isolated by the RNAiso plus (Takara Bio) was reverse-transcribed with PrimeScript RT Master Mix (Takara Bio). Quantitative RT-PCR analysis was performed in an iCycler thermal cycler (Bio-Rad Laboratories, Hercules, CA) using SYBR Premix Ex TaqII (Takara Bio). The quantitative RT-PCR method has been previously described (30) and the primers used are listed in the Supplemental Table. GAPDH was used as an internal control.

Statistical Analyses

The means for two group data were compared by the unpaired t test. The means for more than two groups were compared by one-way ANOVA followed by Tukey’s multiple comparison. Probability values of P<0.05 or P<0.01 were considered to be significant.


Exogenous hAGP Administration Suppresses Proteinuria and Renal Injury in ADR Mice

After adriamycin injection (ADR mice), hAGP (5 mg/mouse) was intraperitoneally administrated for 5 consecutive days (Figure 1A, treatment schedule). The results show that the urinary albumin to creatinine ratio in ADR mice was significantly reduced from 7 to 21 days in the hAGP-treated group (Figure 1B). Furthermore, the increased plasma cholesterol level observed in the ADR group was significantly suppressed by hAGP administration (Figure 1C). The renal function of each mouse was measured (BUN and serum creatinine), but no significant differences were observed between the control, ADR, and ADR-treated with hAGP groups (Supplemental Figure 1B). Renal histologic analyses at day 21 showed that hAGP significantly suppressed glomerulosclerosis and tubular atrophy in ADR mice (Figure 1D). AGP distribution in the kidney was confirmed by immunofluorescence staining using anti-AGP antibody. Fluorescence was largely detected in the glomerulus in control mice, but was markedly decreased in the ADR-treated group. In contrast, similar levels of fluorescence in glomeruli were observed in control mice and ADR mice administered with hAGP (Figure 1E).

Figure 1.:
Exogenous hAGP administration suppresses proteinuria and renal injury in ADR mice. (A) Schedule of human α1-acid glycoprotein (hAGP) treatment. BALB/c mice were administered with hAGP (5 mg/mouse) for 5 consecutive days after adriamycin (ADR) injection. Mice were sacrificed at day 21. (B) Urinary albumin to creatinine ratio at day 7 and day 21 after ADR injection. (C) Total plasma cholesterol at day 21 after ADR injection. (D) Representative periodic acid-Schiff-stained sections at day 21 after ADR injection, and quantitation of evaluation of glomerulosclerosis and tubule damage. Scale bars, 100 μm (control n=5; ADR and ADR+hAGP, n=6). (E) Representative fluorescence photomicrographs showing AGP localization in kidney at day 21. The glomeruli are enclosed in a white dotted line. Scale bars, 100 μm. Red: AGP (n=4 per group) (F) Expression of mouse α1-acid glycoprotein (mAGP) mRNA in liver was determined by quantitative RT-PCR (control n=5; ADR and ADR+hAGP, n=6). (G) Level of endogenous mAGP in plasma and urine determined by western blot analysis (control, n=3; ADR, n=4). nd, not detected. All data are mean ± SE *P<0.05, **P<0.01; by one-way ANOVA and post hoc Tukey’s multiple comparison.

Because plasma AGP levels are upregulated during inflammation, we examined the change in levels of endogenous mouse AGP (mAGP) in plasma of ADR mice by western blotting. Although ADR injection increased the expression of AGP mRNA (Orm1, Orm2, and Orm3) in liver (Figure 1F), plasma mAGP tended to decrease between 7 and 21 days. In contrast to plasma levels, urinary mAGP was increased in ADR mice (Figure 1G). These data suggest that although mAGP production is increased in renal inflammation induced by ADR injection, plasma mAGP levels do not increase due to its higher levels of urinary excretion.

Exogenous hAGP Administration Exerts Anti-inflammatory Effects in Kidneys of ADR Mice

To evaluate the inflammatory condition, kidney sections were stained with anti-F4/80 antibody, a representative macrophage marker. The results show that hAGP administration significantly decreases macrophage infiltration (Figure 2A). It has been reported that the expression of TGF-β increases in damaged glomerular cells including podocytes, whereas IL-1β is produced by macrophages infiltrating into the glomerulus (31,32). Therefore, levels of mRNA for TGF-β and IL-1β were measured. As shown in Figure 2, B and C, TGF-β and IL-1β were significantly decreased in ADR mice treated with hAGP. Interestingly, hAGP administration significantly increased CD163 mRNA levels but did not increased CD206 mRNA levels in kidney. Both of these molecules are representative M2 macrophage markers (Figure 2, D and E), whereas the expression of inducible nitric oxide synthase (iNOS), which is used as an M1 macrophage marker, significantly decrease in the hAGP-administered group (Figure 2F). Moreover, in the hAGP-administered group, there was significantly increased expression of IL-10 compared with control mice (Figure 2G).

Figure 2.:
Exogenous hAGP administration exerts an anti-inflammatory effect in kidneys of ADR mice. (A) Representative micrographs of kidneys at day 21 after ADR injection, stained with antibody against F4/80+ macrophages, and quantitative evaluation of F4/80+ cells. Scale bars, 100 μm (n=4 per group) (B–G) Expression levels of TGF-β, IL-1β, CD163, CD206, inducible nitric oxide synthase (iNOS), and IL-10 mRNAs in kidney at day 21 after ADR injection were determined by quantitative RT-PCR (control, n=5; ADR and ADR+hAGP, n=6). All data are mean ± SE; *P<0.05; by one-way ANOVA and post hoc Tukey’s multiple comparison.

Exogenous hAGP Administration Induces a CD163-Expressing Macrophage Phenotype at Day 7 in ADR Mice

Although hAGP administration significantly decreased the urinary albumin to creatinine ratio at day 7 (Figure 1B), neither renal histologic damage nor infiltration of macrophages were found in any of the three groups (control, ADR, and ADR + hAGP) (Figure 3, A and C). Compared with control mice, nephrin expression as an indicator of podocyte injury was decreased in ADR mice treated with/or without hAGP at day 7 (Figure 3B). On the other hand, the localization of AGP to the glomerulus was increased by hAGP administration in ADR mice at day 7 (Figure 3B). Under the same experimental conditions, hAGP administration suppressed adriamycin-induced TGF-β mRNA expression (Figure 3E), whereas no significant change in IL-1β mRNA expression was found in any of the three groups (Figure 3E). Because the infiltration of macrophages was not changed between the ADR and hAGP-treated ADR groups (Figure 3C), we isolated macrophages from kidney to evaluate the macrophage phenotype. As shown in Figure 4A, the mRNA expression of CD163 was decreased in macrophages from ADR mice, whereas hAGP administration tended to increase the mRNA expression of CD163 (Figure 4A). Next, we administered hAGP to control mice and measured the mRNA expression of CD163 and CD206 in the isolated macrophages. Although the glomerular fluorescence intensities of AGP were not significantly changed between control and hAGP-treated control mice, hAGP administration significantly increased CD163-expressing renal macrophages, even in the control mice (Figure 4B).

Figure 3.:
Exogenous hAGP administration induces an M2-like macrophage phenotype at day 7 in ADR mice. (A) Representative periodic acid-Schiff-stained sections at day 7 after ADR injection, and quantitative of evaluation of glomerulosclerosis and tubule damage (control, n=5; ADR and ADR+hAGP, n=6). Scale bars, 100 μm. (B) Representative fluorescence photomicrographs showing nephrin and AGP localization in glomeruli at day 7. The glomeruli are enclosed in a white dotted line. Green: nephrin; red: AGP (Control, n=3; ADR and ADR+hAGP, n=5). (C) Representative micrographs of kidney at day 7 after ADR injection, stained with antibody against F4/80+ macrophages and quantitative evaluation of F4/80+ cells (n=4 per group). Scale bars, 100 μm. (D and E) Levels of expression of TGF-β and IL-1β mRNAs in kidney at day 7 after ADR injection were determined by quantitative RT-PCR (control, n=5; ADR and ADR+hAGP, n=6). All data are mean ± SE; *P< 0.05; by one-way ANOVA and post hoc Tukey’s multiple comparison.
Figure 4.:
Exogenous administration of hAGP induces CD163-expressing renal macrophages. (A) The mRNA expression of CD163 and CD206 in renal macrophages at day 7 after ADR injection (control, n=4; ADR and ADR+hAGP, n=6). (B) Representative fluorescence photomicrographs showing AGP localization in control and control+hAGP mice. The expression of CD163 and CD206 mRNAs in renal macrophages in control and control+hAGP mice (control, n=5; control+hAGP, n=5). All data are mean ± SE; *P< 0.05; by one-way ANOVA and post hoc Tukey’s multiple comparison or unpaired t test.

hAGP Treatment Switches PMA-Differentiated THP-1 Cells into CD163-Expressing Macrophages

To further study the effect of hAGP on the plasticity of macrophage phenotypes, PMA-differentiated THP-1 cells, a macrophage-like cell type, were treated with hAGP. Because hAGP circulates at 0.5 mg/ml in the plasma of healthy humans and levels increase to 1.0–2.5 mg/ml during inflammation, in vitro experiments were performed using these plasma concentrations of hAGP. Expression of CD163 mRNA was increased by hAGP in a dose-dependent manner, consistent with our previous results (23). In addition, we found that hAGP dose-dependently decreased the expression of CD206 and iNOS mRNA (Figure 5, B and C). These in vitro data are consistent with the changes in renal expression of CD163 and iNOS mRNA shown in Figures 2 and 4. Interestingly, hAGP also dose-dependently increased the expression of IL-10 mRNA (Figure 5D). The changes of CD163 and CD206 expression in macrophages treated with hAGP were compared with those in IL-4/IL-13- or IL-4-treated macrophages, a representative M2 macrophage phenotype. IL-4/IL-13 or IL-4 treatment did not result in an increase in CD163 expression in macrophages, whereas CD206 expression was significantly increased (Figure 5, E and F).

Figure 5.:
AGP treatment switches PMA-differentiated THP-1 cells into M2-like macrophages. (A–D) The expression of CD163, CD206, iNOS, and IL-10 mRNAs in PMA-differentiated THP-1 cells treated with AGP (0–2.5 mg/ml) for 48 hours (n=6 per group). (E and F) Expression of CD163 and CD206 mRNAs in PMA-differentiated THP-1 cells treated with AGP (1.0 mg/ml) or IL-4 (20 ng/ml), and IL-13 (20 ng/ml) or IL-4 (30 ng/ml), for 24 hours (n=3 per group). All data are mean ± SE *P< 0.05, **P<0.01; by one-way ANOVA and post hoc Tukey’s multiple comparison.

The AGP-Induced CD163-Expressing Macrophage Phenotype has Anti-Inflammatory Properties

Next, we compared the phenotypic and anti-inflammatory properties of macrophages treated with AGP or IL-4/IL-13 under inflammatory conditions. As shown in Figure 6, hAGP- or IL-4/IL-13-induced macrophages maintained their phenotypes even after LPS challenge for 2 hours. The expression of IL-10 mRNA was measured after stimulation with LPS for 2 hours after treatment with either AGP or IL-4/IL-13. Interestingly, AGP-treated macrophages had a greater ability to induce IL-10 expression compared with IL-4/IL-13-treated macrophages (Figure 6D).

Figure 6.:
The hAGP-induced macrophage phenotype demonstrates anti-inflammatory properties. (A–D) The expression of CD163, CD206, iNOS, and IL-10 mRNAs in PMA-differentiated THP-1 cells stimulated with LPS (100 ng/ml) for 2 hours after treatment with AGP (1.0 mg/ml), or IL-4 (10 ng/ml) and IL-13 (10 ng/ml), for 24 hours (n=4 per group). All data are mean ± SE *P< 0.05, **P<0.01; by one-way ANOVA and post hoc Tukey’s multiple comparison.


In this study, we found that AGP potentiates the change of macrophage phenotype to CD163-expressing macrophages with anti-inflammatory functions in vivo, thereby reducing proteinuria, inflammation, and renal damage.

Although AGP-induced CD163-expressing macrophages have M2-like properties, they differ from IL-4/IL-13-induced M2 macrophages (Figure 5). Both CD163 and CD206 are normally used as markers of M2 macrophages (33,34), but the changes in expression of each marker are not always consistent during macrophage activation switching. For example, Porcheray et al. showed that IL-4 induced CD206 but not CD163 in human monocyte-derived macrophages. In contrast, IL-10 induced CD163 but not CD206 under the same conditions (33). These results are similar to the characteristics of hAGP-treated macrophages, as shown in Figure 5. Moreover, Furuhashi et al. (26) previously reported that adipose-derived stromal cells induce both CD163+ macrophages and CD206+ macrophages in crescentic GN rats, and that CD163+ macrophages had higher levels of IL-10 expression compared with CD206+ macrophages. This observation is in agreement with the our results, which show that hAGP-induced CD163+ macrophages have increased IL-10 production ability compared with IL-4/IL-13-induced CD206+ macrophages (Figure 6). Previously, we reported that hAGP increases CD163 and IL-10 via weak stimulation of the TLR4/CD14 pathway (23). Subsequently, Nakamura et al. reported that ORM1, one of the AGP variants, induces M2b monocytes in vitro (35) and produces IL-10, which is known to be induced by TLR4 signals. Therefore, the AGP-induced CD163-expressing macrophages found in this study may correspond to M2b macrophages, which are also known as regulatory macrophages. It is recognized that regulatory macrophages produce high levels of IL-10, which limits inflammation by suppressing the production and activation of various proinflammatory cytokines. Although IL-4/IL-13-induced macrophages are also effective against inflammatory disease, they have the potential to increase the risk of tissue fibrosis (36,37). On the other hand, regulatory macrophages have low fibrotic potential compared with IL-4/IL-13-induced macrophages (38). Therefore, it is unlikely that hAGP-induced CD163-expressing macrophages have the potential to induce renal fibrosis. This is supported by our recent study in which exogenously administered hAGP suppressed unilateral ureter obstruction-induced renal fibrosis in a mouse model (27).

Administration of hAGP inhibited urinary albumin in ADR mice between days 7 and 21. However, renal histologic damage and infiltration of macrophages in ADR mice were markedly weaker at day 7 than at day 21. Reflecting these data, the expression of IL-1β mRNA was not changed in ADR mice because IL-1β is produced by infiltrating glomerular macrophages. These results imply that other mechanisms may be involved in the decrease in urinary albumin in hAGP-treated mice at day 7. The glomerular barrier has both size and negative charge selectivity. Negative charge selectivity is a result of the endothelial cell surface layer (ESL), which functions to suppress albumin leakage into urine (394041). Interestingly, AGP is localized at the ESL and contributes to the negative charge barrier in glomeruli because AGP is a highly negative charged protein resulting from the presence of sialylated N-glycans (pI of 2.8–3.8) (13). Hjalmarsson et al. (42) reported that the administration of hAGP increased negative charges at the ESL and improved podocyte morphology in rats with puromycin aminonucleoside-induced nephrosis. Our study found that localization of AGP in the glomerulus was increased by hAGP treatment at day 7 (Figure 3B). Because it has been reported that damaged glomerular cells such as podocytes produced TGF-β, the increased glomerular localization of AGP might contribute to the inhibition of TGF-β mRNA expression in ADR mice (Figure 3D). In addition, these data suggest that administered hAGP might be localized for at least 3 days in the glomerulus and hence might contribute to the suppression of proteinuria at day 7. On the other hand, increased glomerular localization of hAGP was not found in hAGP-treated control mice (Figure 4B). This result indicates that the accumulation of AGP may require a decreasing negative charge in the glomerulus. Further investigation would be needed to elucidate the role of exogenously administered hAGP on glomerular negative charge selectivity in the future. In addition, the anti-AGP (ORM1) antibody used in this study has cross reactivity with hAGP and mAGP. Therefore, we could not clearly distinguish whether the localization of AGP in the glomerulus came from endogenous or exogenous AGP under our experimental conditions. Further study may be needed using hAGP- or mAGP-specific antibodies if such antibodies are commercially available.

In conclusion, this study indicates that AGP has a unique mechanism in regulating inflammation and has the potential to suppress urinary protein levels by targeting the ESL. The results showed that endogenous AGP could work to protect against glomerular disease. Because proteinuria is an independent risk factor for CKD progression and CVD onset (2,3), it is speculated that alleviation of proteinuria and protection against renal tissue damage by AGP could be a new therapeutic strategy for CKD such as nephrosis, and diabetic nephropathy and CVD. Future investigation is needed to evaluate if AGP is also protective if given in a later phase of the disease.


M. Fukagawa reports grants and personal fees from Kyoto Kirin and Ono Pharmaceutical, and personal fees from Bayer Japan. M. Tanaka reports personal fees from Torii and Kyowa Kirin. J. Bi, R. Fujimura, Y. Fujiwara, T. Imafuku, K. Kobayashi, T. Koga, H. Komori, H. Maeda, T. Maruyama, K. Matsushita, M. Miyahisa, K. Nishida, T. Wada, and H. Watanabe have nothing to disclose.


This work was supported in part by Grant-in-Aid for Challenging Exploratory Research grant 16K15320, Japan Society for the Promotion of Science Fellows grant 18J23070, and the KUMAYAKU Alumni Research Foundation.

Author Contributions

R. Fujimura, H. Watanabe, and T. Maruyama conceptualized the study; J. Bi, R. Fujimura, Y. Fujiwara, T. Imafuku, K. Kobayashi, T. Koga, H. Komori, M. Miyahisa, K. Nishida, and H. Maeda were responsible for investigation; R. Fujimura was responsible for formal analysis, visualization, and the original draft of the manuscript; H. Watanabe and T. Maruyama were responsible for funding acquisition, project administration, and supervision; R. Fujimura, Y. Fujiwara, T. Koga, H. Watanabe, and T. Maruyama were responsible for methodology; R. Fujimura, H. Watanabe, and T. Maruyama were responsible for data curation; R. Fujimura, Y. Fujiwara, T. Koga, H. Watanabe, and T. Maruyama were responsible for resources; and R. Fujimura, H. Watanabe, Y. Fujiwara, T. Koga, H. Maeda, M. Tanaka, K. Matsushita, T. Wada, M. Fukagawa, and T. Maruyama reviewed and edited the manuscript.

K360: This article contains supplemental material online at http://kidney360.asnjournals.org/lookup/suppl/doi:10.34067/KID.0000782019/-/DCSupplemental.


1. Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, Hobbs FDR: Global prevalence of chronic kidney disease - A systematic review and meta-analysis. PLoS One 11: e0158765, 2016
2. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT; Chronic Kidney Disease Prognosis Consortium: Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis. Lancet 375: 2073–2081, 2010
3. van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A, de Jong P, Gansevoort RT, van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey AS, de Jong PE, Gansevoort RT, Levey A, El-Nahas M, Eckardt KU, Kasiske BL, Ninomiya T, Chalmers J, Macmahon S, Tonelli M, Hemmelgarn B, Sacks F, Curhan G, Collins AJ, Li S, Chen SC, Hawaii Cohort KP, Lee BJ, Ishani A, Neaton J, Svendsen K, Mann JF, Yusuf S, Teo KK, Gao P, Nelson RG, Knowler WC, Bilo HJ, Joosten H, Kleefstra N, Groenier KH, Auguste P, Veldhuis K, Wang Y, Camarata L, Thomas B, Manley T; Chronic Kidney Disease Prognosis Consortium: Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int 79: 1341–1352, 2011
4. Nagata M, Ninomiya T, Kiyohara Y, Murakami Y, Irie F, Sairenchi T, Miura K, Okamura T, Ueshima H; EPOCH-JAPAN Research Group: Prediction of cardiovascular disease mortality by proteinuria and reduced kidney function: Pooled analysis of 39,000 individuals from 7 cohort studies in Japan. Am J Epidemiol 178: 1–11, 2013
5. Ordoñez JD, Hiatt RA, Killebrew EJ, Fireman BH: The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 44: 638–642, 1993
6. Abbate M, Zoja C, Remuzzi G: How does proteinuria cause progressive renal damage? J Am Soc Nephrol 17: 2974–2984, 2006
7. Silverstein DM: Inflammation in chronic kidney disease: Role in the progression of renal and cardiovascular disease. Pediatr Nephrol 24: 1445–1452, 2009
8. Wang Y, Harris DC: Macrophages in renal disease. J Am Soc Nephrol 22: 21–27, 2011
9. Cao Q, Wang Y, Harris DC: Pathogenic and protective role of macrophages in kidney disease. Am J Physiol Renal Physiol 305: F3–F11, 2013
10. Liu YC, Zou XB, Chai YF, Yao YM: Macrophage polarization in inflammatory diseases. Int J Biol Sci 10: 520–529, 2014
11. Lee S, Huen S, Nishio H, Nishio S, Lee HK, Choi BS, Ruhrberg C, Cantley LG: Distinct macrophage phenotypes contribute to kidney injury and repair. J Am Soc Nephrol 22: 317–326, 2011
12. Wang Y, Wang YP, Zheng G, Lee VW, Ouyang L, Chang DH, Mahajan D, Coombs J, Wang YM, Alexander SI, Harris DC: Ex vivo programmed macrophages ameliorate experimental chronic inflammatory renal disease. Kidney Int 72: 290–299, 2007
13. Fournier T, Medjoubi-N N, Porquet D: Alpha-1-acid glycoprotein. Biochim Biophys Acta 1482: 157–171, 2000
14. Hochepied T, Berger FG, Baumann H, Libert C: Alpha(1)-acid glycoprotein: An acute phase protein with inflammatory and immunomodulating properties. Cytokine Growth Factor Rev 14: 25–34, 2003
15. Edwards DJ, Lalka D, Cerra F, Slaughter RL: Alpha1-acid glycoprotein concentration and protein binding in trauma. Clin Pharmacol Ther 31: 62–67, 1982
16. Arai H, Tomizawa S, Maruyama K, Seki Y, Kuroume T: Reversed-phase high-performance liquid chromatography for analysis of urinary proteins: Diagnostic significance of alpha 1-acid glycoprotein. Nephron 66: 278–284, 1994
17. Bennett MR, Pleasant L, Haffner C, Ma Q, Haffey WD, Ying J, Wagner M, Greis KD, Devarajan P: A novel biomarker panel to identify steroid resistance in childhood idiopathic nephrotic syndrome. Biomark Insights 12: 1177271917695832, 2017
18. Costello MJ, Gewurz H, Siegel JN: Inhibition of neutrophil activation by alpha1-acid glycoprotein. Clin Exp Immunol 55: 465–472, 1984
19. Lainé E, Couderc R, Roch-Arveiller M, Vasson MP, Giroud JP, Raichvarg D: Modulation of human polymorphonuclear neutrophil functions by alpha 1-acid glycoprotein. Inflammation 14: 1–9, 1990
20. Chiu KM, Mortensen RF, Osmand AP, Gewurz H: Interactions of alpha1-acid glycoprotein with the immune system. I. Purification and effects upon lymphocyte responsiveness. Immunology 32: 997–1005, 1977
21. Bories PN, Guenounou M, Féger J, Kodari E, Agneray J, Durand G: Human alpha 1-acid glycoprotein-exposed macrophages release interleukin 1 inhibitory activity. Biochem Biophys Res Commun 147: 710–715, 1987
22. Daemen MA, Heemskerk VH, van’t Veer C, Denecker G, Wolfs TG, Vandenabeele P, Buurman WA: Functional protection by acute phase proteins alpha(1)-acid glycoprotein and alpha(1)-antitrypsin against ischemia/reperfusion injury by preventing apoptosis and inflammation. Circulation 102: 1420–1426, 2000
23. Komori H, Watanabe H, Shuto T, Kodama A, Maeda H, Watanabe K, Kai H, Otagiri M, Maruyama T: α(1)-Acid glycoprotein up-regulates CD163 via TLR4/CD14 protein pathway: Possible protection against hemolysis-induced oxidative stress. J Biol Chem 287: 30688–30700, 2012
24. Mosser DM: The many faces of macrophage activation. J Leukoc Biol 73: 209–212, 2003
25. Alvarado-Vazquez PA, Bernal L, Paige CA, Grosick RL, Moracho Vilrriales C, Ferreira DW, Ulecia-Morón C, Romero-Sandoval EA: Macrophage-specific nanotechnology-driven CD163 overexpression in human macrophages results in an M2 phenotype under inflammatory conditions. Immunobiology 222: 900–912, 2017
26. Furuhashi K, Tsuboi N, Shimizu A, Katsuno T, Kim H, Saka Y, Ozaki T, Sado Y, Imai E, Matsuo S, Maruyama S: Serum-starved adipose-derived stromal cells ameliorate crescentic GN by promoting immunoregulatory macrophages. J Am Soc Nephrol 24: 587–603, 2013
27. Bi J, Watanabe H, Fujimura R, Nishida K, Nakamura R, Oshiro S, Imafuku T, Komori H, Miyahisa M, Tanaka M, Matsushita K, Maruyama T: A downstream molecule of 1,25-dihydroxyvitamin D3, alpha-1-acid glycoprotein, protects against mouse model of renal fibrosis. Sci Rep 8: 17329, 2018
28. Cao Q, Wang C, Zheng D, Wang Y, Lee VW, Wang YM, Zheng G, Tan TK, Yu D, Alexander SI, Harris DC, Wang Y: IL-25 induces M2 macrophages and reduces renal injury in proteinuric kidney disease. J Am Soc Nephrol 22: 1229–1239, 2011
29. Cao Q, Wang Y, Wang XM, Lu J, Lee VW, Ye Q, Nguyen H, Zheng G, Zhao Y, Alexander SI, Harris DC: Renal F4/80+ CD11c+ mononuclear phagocytes display phenotypic and functional characteristics of macrophages in health and in adriamycin nephropathy. J Am Soc Nephrol 26: 349–363, 2015
30. Enoki Y, Watanabe H, Arake R, Fujimura R, Ishiodori K, Imafuku T, Nishida K, Sugimoto R, Nagao S, Miyamura S, Ishima Y, Tanaka M, Matsushita K, Komaba H, Fukagawa M, Otagiri M, Maruyama T: Potential therapeutic interventions for chronic kidney disease-associated sarcopenia via indoxyl sulfate-induced mitochondrial dysfunction. J Cachexia Sarcopenia Muscle 8: 735–747, 2017
31. Kim JH, Kim BK, Moon KC, Hong HK, Lee HS: Activation of the TGF-beta/Smad signaling pathway in focal segmental glomerulosclerosis. Kidney Int 64: 1715–1721, 2003
32. Matsumoto K: Production of interleukin-1 by glomerular macrophages in nephrotoxic serum nephritis. Am J Nephrol 10: 502–506, 1990
33. Porcheray F, Viaud S, Rimaniol AC, Léone C, Samah B, Dereuddre-Bosquet N, Dormont D, Gras G: Macrophage activation switching: An asset for the resolution of inflammation. Clin Exp Immunol 142: 481–489, 2005
34. Biswas SK, Mantovani A: Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm. Nat Immunol 11: 889–896, 2010
35. Nakamura K, Ito I, Kobayashi M, Herndon DN, Suzuki F: Orosomucoid 1 drives opportunistic infections through the polarization of monocytes to the M2b phenotype. Cytokine 73: 8–15, 2015
36. Borthwick LA, Barron L, Hart KM, Vannella KM, Thompson RW, Oland S, Cheever A, Sciurba J, Ramalingam TR, Fisher AJ, Wynn TA: Macrophages are critical to the maintenance of IL-13-dependent lung inflammation and fibrosis. Mucosal Immunol 9: 38–55, 2016
37. Jakubzick C, Kunkel SL, Puri RK, Hogaboam CM: Therapeutic targeting of IL-4- and IL-13-responsive cells in pulmonary fibrosis. Immunol Res 30: 339–349, 2004
38. Fleming BD, Mosser DM: Regulatory macrophages: Setting the threshold for therapy. Eur J Immunol 41: 2498–2502, 2011
39. Haraldsson B, Nyström J, Deen WM: Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev 88: 451–487, 2008
40. Hjalmarsson C, Johansson BR, Haraldsson B: Electron microscopic evaluation of the endothelial surface layer of glomerular capillaries. Microvasc Res 67: 9–17, 2004
41. Jeansson M, Björck K, Tenstad O, Haraldsson B: Adriamycin alters glomerular endothelium to induce proteinuria. J Am Soc Nephrol 20: 114–122, 2009
42. Hjalmarsson C, Lidell ME, Haraldsson B: Beneficial effects of orosomucoid on the glomerular barrier in puromycin aminonucleoside-induced nephrosis. Nephrol Dial Transplant 21: 1223–1230, 2006

CKD; α1-acid glycoprotein; macrophage polarization; proteinuria; Basic Science

Copyright © 2020 by the American Society of Nephrology